Antimicrobial claims for antigingivitis/plaque agents not supported -- subcommittee.
This article was originally published in The Rose Sheet
Executive Summary
ANTIGINGIVITIS AGENTS "ANTIMICROBIAL" STATEMENT OF IDENTITY is "not consistent" with the deliberations of FDA's Dental Plaque Subcommittee, Sheila McGuire-Riggs, DDS, Wellmark, Blue Cross/Blue Shield of Iowa, declared at its May 28 meeting in Gaithersburg, Md. The advisory group met to continue the development of FDA's OTC antigingivitis drug products monograph and to discuss specific labeling and final formulation testing requirements for products included in the rulemaking.
You may also be interested in...
FDA May Amend Anticaries Monograph To Allow Combo Antiplaque Products
FDA may be amenable to an oral rinse product that crosses the anticaries and antiplaque/antigingivitis monographs if studies demonstrate safety and efficacy, agency officials told Warner-Lambert at an OTC "feedback" meeting in Rockville, Md. Oct. 8.
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program